Effective March 1, 2026, new procurement agreements will be in place for infliximab prescriptions, ranked by price.
- Zessly, priced at 473.70 Swedish krona per 100 mg of infliximab.
- Flixabi, price per 100 mg of infliximab (price confidential).
- Remicade, priced at 1,549 Swedish krona per 100 mg of infliximab.
All purchases of Remsima, which was previously the first-line option, will be made at the product’s list price starting March 1, currently around 2,730 krona per 100 mg of infliximab (as of early 2026).
All healthcare providers treating patients with infliximab prescriptions are encouraged to begin prescribing Zessly first, starting March 1.
The new agreements can be extended until February 28, 2030, at the latest.
New pricing agreements for infliximab prescriptions are set to take effect on March 1, 2026, prioritizing cost-effectiveness for healthcare providers. These changes, impacting the availability of different brands of the medication, aim to streamline purchasing decisions and potentially lower costs for treatment of autoimmune conditions.
Under the new agreements, Zessly will be the most affordable option, priced at 473.70 Swedish krona per 100 mg of infliximab. Flixabi’s price per 100 mg remains confidential, while Remicade will cost 1,549 Swedish krona per 100 mg.
A significant shift involves Remsima, formerly the preferred treatment option. Beginning March 1, all Remsima purchases will be made at the product’s list price, which currently stands at approximately 2,730 krona per 100 mg of infliximab (as of early 2026). This represents a substantial price increase compared to previous arrangements.
Healthcare providers who prescribe infliximab are being advised to prioritize Zessly as the first-line treatment option, starting on March 1. The new procurement agreements will remain in effect, with the possibility of extension, through February 28, 2030.
Infliximab is used to treat a number of autoimmune diseases, including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, and psoriasis. These changes in procurement practices could have implications for access to treatment and overall healthcare costs for patients requiring this medication.
More information about infliximab can be found at Infliximab.com and Wikipedia.
